UnitedHealth, Amedisys and antitrust regulators will have a magistrate judge’s help in hashing out a solution to the DOJ’s ...

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Amedisys' high Quality of Patient Care and Patient Satisfaction star ...

A federal judge in Maryland ordered the Justice Department and UnitedHealth Group to begin mediation on Aug. 18.

The U.S. Department of Justice’s (DOJ) lawsuit against Amedisys Inc. (NASDAQ: AMED) and UnitedHealth Group (NYSE: UNH) will ...

Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Sell-side analysts expect that Amedisys will post 4.4 earnings per share for the current year. Hedge Funds Weigh In On Amedisys ...

Yet another shoe has dropped in the UnitedHealth Group/Amedisys saga. Last week, the Justice Department — along with the ...

Rating upgraded from 62 to 71 Monday — a welcome improvement, but still shy of the 80 or higher score you look for. Please watch the video at Investors.com - How To Find Game-Changing Stocks This ...

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Department of Justice will head to mediation with UnitedHealth Group and Amedisys April 18 as part of an ongoing antitrust lawsuit. Both companies are attempting to finalize a $3.3 billion ...

RBC Capital analyst Ben Hendrix maintained a Buy rating on Amedisys (AMED – Research Report) yesterday and set a price target of $100.00.Stay ...

It has been about a month since the last earnings report for Amedisys (AMED). Shares have added about 1.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...